

Cover Story
After a courtroom victory against Amgen Inc. this summer, the last of the obstacles was removed for the first biosimilar agent—a white blood cell growth factor—to enter the U.S. market.
By Matthew Bin Han Ong
By Matthew Bin Han Ong
In Brief
Drugs & Targets


Trending Stories
- The Directors: Tom Lynch and Skip Burris on how NIH funding cuts imperil biopharma innovation—and cost patient lives
In a time of uncertainty, “react to the knowns, not the fear” - The faces of RIF: Staff members of NCI’s dissolved communications team gather for a farewell group photo
- How MD Anderson and Texas Children’s made plans to build a $1 billion pediatric cancer hospital—one of the world’s largest
- In the Headlines: What if curing diseases was treated like a business?
- Lou Weisbach tells us about his plan to raise $750 billion for the American Center for Cures
- “Forward funding” NIH budget plan would make competing for grants much harder